Morningstar

Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants

NAZARETH, Israel and PARMA, Italy, June 5, 2025 /PRNewswire/ -- Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 ...
Medical News Today

What tests are used to diagnose short bowel syndrome?

Doctors use laboratory tests, imaging studies, and endoscopic procedures to help diagnose short bowel syndrome, which affects nutrient absorption in the small intestine. Short bowel syndrome (SBS) ...
WDAF-TV

ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants

NAZARETH, Israel, July 19, 2023 /PRNewswire/ -- Elgan Pharma, a late-stage clinical biopharmaceutical company focusing on innovative treatments for critical conditions in neonates, announced today ...
CU Independent

Dr. Umapathy Sundaram on Turning Lab Insights into Digestive Health Advances

Dr. Umapathy Sundaram, known as Uma to colleagues, directs research efforts that translate molecular discoveries into ...